D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
88,700
-1,600 (-1.77%)
Nov 20, 2025, 3:30 PM KST
-1.77%
Market Cap3.92T
Revenue (ttm)9.33B
Net Income (ttm)-37.11B
Shares Out43.43M
EPS (ttm)-873.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume750,289
Average Volume2,642,865
Open90,200
Previous Close90,300
Day's Range86,600 - 92,200
52-Week Range8,088 - 94,100
Betan/a
RSI70.04
Earnings DateNov 14, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.